DNLI Denali Therapeutics Inc.

20.77
+0.37  (+2%)
Previous Close 20.4
Open 20.24
Price To Book 4.27
Market Cap 1972258801
Shares 94,957,092
Volume 348,733
Short Ratio
Av. Daily Volume 369,885

SEC filingsSee all SEC filings

  1. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 181221065
  2. 8-K - Current report 181193079
  3. CT ORDER - Confidential treatment order 181191922
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170216
  5. 8-K - Current report 181170178

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b commencement of dosing announced December 10, 2018. Data due 4Q 2019.
DNL201
Parkinson’s disease
Phase 1 data presented December 2018.
DNL747
Alzheimer’s disease

Latest News

  1. Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
  2. The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
  3. Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
  4. The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings
  5. Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
  6. Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price
  7. Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors
  8. The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal
  9. [$$] Sanofi, Denali Tie Up $1B Deal
  10. Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
  11. Report: Exploring Fundamental Drivers Behind Q2, Badger Meter, Tiffany, Walgreens Boots Alliance, Intrexon, and Denali Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
  12. Where Dallas’ largest hedge funds are placing their long bets
  13. CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
  14. Could Denali Therapeutics Inc’s (NASDAQ:DNLI) Investor Composition Impacts Your Returns?

SEC Filings

  1. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 181221065
  2. 8-K - Current report 181193079
  3. CT ORDER - Confidential treatment order 181191922
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170216
  5. 8-K - Current report 181170178
  6. 8-K - Current report 181151871
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005978
  8. 8-K - Current report 181005654
  9. 8-K - Current report 18985299
  10. CT ORDER - Confidential treatment order 18956191